Skip to main content Skip to navigation
RY586 Mouse Anti-Human CD13
RY586 Mouse Anti-Human CD13
Multiparameter flow cytometric analysis using BD OptiBuild™ RY586 Mouse Anti-Human CD13 antibody (Cat. No. 753418) on human peripheral blood.  Flow cytometry was performed using a BD LSRFortessa™ X-20 Flow Cytometer System.
Multiparameter flow cytometric analysis using BD OptiBuild™ RY586 Mouse Anti-Human CD13 antibody (Cat. No. 753418) on human peripheral blood.  Flow cytometry was performed using a BD LSRFortessa™ X-20 Flow Cytometer System.
Product Details
Down Arrow Up Arrow


BD OptiBuild™
ANPEP; APN; Aminopeptidase N; Alanyl aminopeptidase; LAP1; PEPN
Human (Tested in Development)
Mouse BALB/c X C57BL/6 IgG1, κ
KG-1a Cell Line
Flow cytometry (Qualified)
0.2 mg/ml
V MA21
290
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

Product Notices

  1. Researchers should determine the optimal concentration of this reagent for their individual applications.
  2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  3. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  6. CF™ is a trademark of Biotium, Inc.
  7. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
  8. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  9. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  10. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
753418 Rev. 2
Antibody Details
Down Arrow Up Arrow
L138

The L138 monoclonal antibody (also known as Leu-M7) specifically binds to a glycosylated 150 kDa type II integral membrane zinc-metalloprotease. The CD13 antigen is also known as aminopeptidase N, APN, ANPEP, and gp150. The CD13 antigen is expressed on granulocytes, monocytes, mast cells, and granulocyte/macrophage progenitor cells (CFU-GM), but not on lymphocytes, platelets, or erythrocytes. It is expressed on most acute myeloid leukemia (AML) cells and some chronic myeloid leukemia (CML) cells. The CD13 antigen is also expressed on epithelial cells of the kidney, small intestine, and respiratory tract, as well as in synaptic membranes in the central nervous system (CNS). The CD13 antigen is involved in the metabolism of many regulatory peptides. Clustering of the CD13 antigen by various forms of ligation promotes the adhesion between monocytes and endothelial cells. The CD13 antigen is the receptor for human coronavirus 229E, the causative agent for some cases of upper respiratory infection.

753418 Rev. 2
Format Details
Down Arrow Up Arrow
RY586
The BD Horizon RealYellow™ 586 (RY586) Dye is part of the BD family of yellow-green dyes. It is a small organic fluorochrome with an excitation maximum (Ex Max) at 565-nm and an emission maximum (Em Max) at 586-nm. Driven by BD innovation, RY586 can be used on both spectral and conventional cytometers and is designed to be excited by the Yellow-Green laser (561-nm) with minimal excitation by the 488-nm Blue laser. For conventional instruments equipped with a Yellow-Green laser (561-nm), RY586 can be used as an alternative to PE and we recommend using an optical filter centered near 586-nm (eg, a 586/15-nm bandpass filter). For spectral instruments equipped with a Yellow-Green laser (561-nm), it can be used in conjunction with PE. Compared to PE, RY586 is similar in brightness, minimal spillover into Blue detectors, and increased spillover into the 610/20-nm (PE-CF594) detector. Please ensure that your instrument configuration (lasers and optical filters) is appropriate for this dye.
altImg
RY586
Yellow-Green 561 nm
564 nm
586 nm
753418 Rev.2
Citations & References
Down Arrow Up Arrow

Development References (19)

  1. Gadd S. Cluster report: CD13. In: Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989::782-784.
  2. Ashmun RA, Holmes KV, Shapiro LH, et al. CD13 (aminopeptidase N) cluster workshop report. In: Schlossman SF. Stuart F. Schlossman .. et al., ed. Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993. Oxford: Oxford University Press; 1995::771-775.
  3. Bradstock KF, Favaloro EJ, Kabral A, Kerr A, Hughes WG, Musgrove E. Myeloid progenitor surface antigen identified by monoclonal antibody.. Br J Haematol. 1985; 61(1):11-20. (Biology). View Reference
  4. Büchi G, Girotto M, Baldini G, et al. Differentiation phenotypes on cells of acute myeloid leukemia studied by My7, My9, My4, Mo1 and Ja monoclonal antibodies.. Pathologica. 79(1064):699-704. (Biology). View Reference
  5. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.. J Clin Oncol. 1990; 8(5):813-9. (Biology). View Reference
  6. Drexler HG. Classification of acute myeloid leukemias--a comparison of FAB and immunophenotyping.. Leukemia. 1987; 1(10):697-705. (Biology). View Reference
  7. Foon KA, Gale RP, Todd RF. Recent advances in the immunologic classification of leukemia.. Semin Hematol. 1986; 23(4):257-83. (Biology). View Reference
  8. Griffin JD, Ritz J, Beveridge RP, Lipton JM, Daley JF, Schlossman SF. Expression of MY7 antigen on myeloid precursor cells.. Int J Cell Cloning. 1983; 1(1):33-48. (Biology). View Reference
  9. Howard MR, Thomas L, Reid MM. Variable detection of myeloid antigens in childhood acute lymphoblastic leukaemia.. J Clin Pathol. 1994; 47(11):1006-9. (Clone-specific: Flow cytometry). View Reference
  10. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13).. Blood. 1999; 94(7):2333-42. (Biology). View Reference
  11. Lee SH, Crocker PR, Westaby S, et al. Isolation and immunocytochemical characterization of human bone marrow stromal macrophages in hemopoietic clusters.. J Exp Med. 1988; 168(3):1193-8. (Biology). View Reference
  12. Look AT, Ashmun RA, Shapiro LH, et al. Report on the CD13 (aminopeptidase N) cluster Workshop. In: Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:784-787.
  13. Mina-Osorio P, Winnicka B, O'Conor C, et al. CD13 is a novel mediator of monocytic/endothelial cell adhesion.. J Leukoc Biol. 2008; 84(2):448-59. (Biology). View Reference
  14. Pombo de Oliveira MS, Matutes E, Rani S, Morilla R, Catovsky D. Early expression of MCS2 (CD13) in the cytoplasm of blast cells from acute myeloid leukaemia.. Acta Haematol. 1988; 80(2):61-4. (Biology). View Reference
  15. Sakai K, Hattori T, Sagawa K, Yokoyama M, Takatsuki K. Biochemical and functional characterization of MCS-2 antigen (CD13) on myeloid leukemic cells and polymorphonuclear leukocytes.. Cancer Res. 1987; 47(21):5572-6. (Biology). View Reference
  16. Terstappen LW, Hollander Z, Meiners H, Loken MR. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leukoc Biol. 1990; 48(2):138-148. (Clone-specific: Flow cytometry). View Reference
  17. Yeager CL, Ashmun RA, Williams RK, et al. Human aminopeptidase N is a receptor for human coronavirus 229E.. Nature. 1992; 357(6377):420-2. (Biology). View Reference
  18. Zola H. Leukocyte and stromal cell molecules : the CD markers. Hoboken, N.J.: Wiley-Liss; 2007.
  19. van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012; 26(9):1908-1975. (Clone-specific: Flow cytometry). View Reference
View All (19) View Less
753418 Rev. 2

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.